Affibody: Funding, Investors & Team (Sep 2026)
Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that targets psoriasis, and B-cell driven autoimmune diseases respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. Affibody has ongoing commercial relationships with several companies such as AbClon, Alexion, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Affibody AB is a holding of Patricia Industries.
Affibody has raised $21.2M across 1 funding round on record, the most recent an undisclosed round of $21.2M announced in Dec 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Affibody Company Profile and Key Stats
Latest funding round on record: Dec 2022.
Affibody Funding Rounds
Affibody Founders and Leadership Team
No contact details are on record for this team yet.
Affibody Funding Compared to Other Biotechnology Startups
Affibody's latest round of $21.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Affibody in Biotechnology and Stockholm
Companies Similar to Affibody
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic…
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.
Our vision is to develop and bring to the market safe and effective treatments for women specific diseases…
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer…
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for…
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for…
Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular…
Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge…
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in…
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic…
ArgusEye is a biotech firm that offers sensor solutions for instant identification of biological systems and…
Affibody Funding FAQs
What does Affibody do?
Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that targets psoriasis, and B-cell driven autoimmune diseases respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. Affibody has ongoing commercial relationships with several companies such as AbClon, Alexion, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Affibody AB is a holding of Patricia Industries.
How much funding has Affibody raised?
Affibody has raised $21.2M across 1 round on record. The most recent is an undisclosed round of $21.2M announced in Dec 2022.
When did Affibody last raise funding?
Affibody's most recent funding round on record is an undisclosed round of $21.2M, announced in Dec 2022.
Who is the CEO of Affibody?
David Bejker is listed as CEO at Affibody.
Where is Affibody headquartered?
Affibody is based in Stockholm, Stockholms Lan, Sweden.
How many employees does Affibody have?
Affibody is in the 101-250 employee band.
How does Affibody's funding compare to other Biotechnology startups?
Affibody's latest round of $21.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Affibody Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Affibody is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.